Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 2013. The document serves as a notification of transactions involving Directors and Persons Discharging Managerial Responsibility regarding their interests in the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is strictly a disclosure of share transactions and does not contain financial performance data.
Material Changes
The filing details the acquisition of Ordinary Shares by various directors and executives on March 11, 2013, through the Company's ShareReward Plan. The purchase price was 1490.69 pence per Ordinary Share. Transactions included both personal contributions and matching company contributions.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the notification of specific share acquisitions in compliance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Facts for Investor Verification
- Transaction Date: March 11, 2013.
- Share Price: 1490.69 pence per Ordinary Share.
- Participants: Sir Andrew Witty, Mr S Dingemans, Mr S M Bicknell, Mr R G Connor, Mr D S Redfern, Ms C Thomas, Mr P C Thomson, Dr P J T Vallance, Ms E Walmsley, and Mrs V A Whyte.
- Transaction Type: Acquisitions under the ShareReward Plan (personal and matching elements).
- Notification Date: March 12, 2013.